Literature DB >> 18483625

A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition.

Alberto J Schuhmacher1, Carmen Guerra, Vincent Sauzeau, Marta Cañamero, Xosé R Bustelo, Mariano Barbacid.   

Abstract

Germline activation of H-RAS oncogenes is the primary cause of Costello syndrome (CS), a neuro-cardio-facio-cutaneous developmental syndrome. Here we describe the generation of a mouse model of CS by introduction of an oncogenic Gly12Val mutation in the mouse H-Ras locus using homologous recombination in ES cells. Germline expression of the endogenous H-RasG12V oncogene, even in homozygosis, resulted in hyperplasia of the mammary gland. However, development of tumors in these mice was rare. H-RasG12V mutant mice closely phenocopied some of the abnormalities observed in patients with CS, including facial dysmorphia and cardiomyopathies. These mice also displayed alterations in the homeostasis of the cardiovascular system, including development of systemic hypertension, extensive vascular remodeling, and fibrosis in both the heart and the kidneys. This phenotype was age dependent and was a consequence of the abnormal upregulation of the renin-Ang II system. Treatment with captopril, an inhibitor of Ang II biosynthesis, prevented development of the hypertension condition, vascular remodeling, and heart and kidney fibrosis. In addition, it partially alleviated the observed cardiomyopathies. These mice should help in elucidating the etiology of CS symptoms, identifying additional defects, and evaluating potential therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483625      PMCID: PMC2381749          DOI: 10.1172/JCI34385

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  57 in total

Review 1.  Gene targeting approaches to analyzing hypertension.

Authors:  N Takahashi; O Smithies
Journal:  J Am Soc Nephrol       Date:  1999-07       Impact factor: 10.121

2.  Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development.

Authors:  Nieves Mijimolle; Juan Velasco; Pierre Dubus; Carmen Guerra; Carolyn A Weinbaum; Patrick J Casey; Victoria Campuzano; Mariano Barbacid
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 3.  Tumor predisposition in Costello syndrome.

Authors:  Karen W Gripp
Journal:  Am J Med Genet C Semin Med Genet       Date:  2005-08-15       Impact factor: 3.908

4.  pMECA: a cloning plasmid with 44 unique restriction sites that allows selection of recombinants based on colony size.

Authors:  J M Thomson; W A Parrott
Journal:  Biotechniques       Date:  1998-06       Impact factor: 1.993

Review 5.  Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.

Authors:  Saïd M Sebti
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Dicistronic targeting constructs: reporters and modifiers of mammalian gene expression.

Authors:  P Mountford; B Zevnik; A Düwel; J Nichols; M Li; C Dani; M Robertson; I Chambers; A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

Authors:  D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

8.  Myocardial storage of chondroitin sulfate-containing moieties in Costello syndrome patients with severe hypertrophic cardiomyopathy.

Authors:  Aleksander Hinek; Michael A Teitell; Lisa Schoyer; William Allen; Karen W Gripp; Robert Hamilton; Rosanna Weksberg; Michael Klüppel; Angela E Lin
Journal:  Am J Med Genet A       Date:  2005-02-15       Impact factor: 2.802

Review 9.  Protein prenylation: molecular mechanisms and functional consequences.

Authors:  F L Zhang; P J Casey
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

10.  Germline mutations in HRAS proto-oncogene cause Costello syndrome.

Authors:  Yoko Aoki; Tetsuya Niihori; Hiroshi Kawame; Kenji Kurosawa; Hirofumi Ohashi; Yukichi Tanaka; Mirella Filocamo; Kumi Kato; Yoichi Suzuki; Shigeo Kure; Yoichi Matsubara
Journal:  Nat Genet       Date:  2005-09-18       Impact factor: 38.330

View more
  56 in total

1.  Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells.

Authors:  Cristina Santoriello; Gianluca Deflorian; Federica Pezzimenti; Koichi Kawakami; Luisa Lanfrancone; Fabrizio d'Adda di Fagagna; Marina Mione
Journal:  Dis Model Mech       Date:  2008-12-22       Impact factor: 5.758

2.  In vivo severity ranking of Ras pathway mutations associated with developmental disorders.

Authors:  Granton A Jindal; Yogesh Goyal; Kei Yamaya; Alan S Futran; Iason Kountouridis; Courtney A Balgobin; Trudi Schüpbach; Rebecca D Burdine; Stanislav Y Shvartsman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

3.  Studying Metabolic Abnormalities in the Costello Syndrome HRAS G12V Mouse Model: Isolation of Mouse Embryonic Fibroblasts and Their In Vitro Adipocyte Differentiation.

Authors:  Miray Fidan; Saravanakkumar Chennappan; Ion Cristian Cirstea
Journal:  Methods Mol Biol       Date:  2021

4.  Ras history: The saga continues.

Authors:  Adrienne D Cox; Channing J Der
Journal:  Small GTPases       Date:  2010-07

5.  Cardiomyopathies in Noonan syndrome and the other RASopathies.

Authors:  Bruce D Gelb; Amy E Roberts; Marco Tartaglia
Journal:  Prog Pediatr Cardiol       Date:  2015-07-01

6.  An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.

Authors:  Karen W Gripp; Katia Sol-Church; Patroula Smpokou; Gail E Graham; David A Stevenson; Heather Hanson; David H Viskochil; Laura C Baker; Bridget Russo; Nick Gardner; Deborah L Stabley; Verena Kolbe; Georg Rosenberger
Journal:  Am J Med Genet A       Date:  2015-04-25       Impact factor: 2.802

7.  HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.

Authors:  A Omrani; T van der Vaart; E Mientjes; G M van Woerden; M R Hojjati; K W Li; D H Gutmann; C N Levelt; A B Smit; A J Silva; S A Kushner; Y Elgersma
Journal:  Mol Psychiatry       Date:  2015-04-28       Impact factor: 15.992

Review 8.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

Review 9.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

Review 10.  A New View of Ras Isoforms in Cancers.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Mayukh Chakrabarti; Hyunbum Jang
Journal:  Cancer Res       Date:  2015-12-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.